Differences in SMN1 allele frequencies among ethnic groups within North America.
paper
Cited
Public
- Authors
- Hendrickson, B C; Donohoe, C; Akmaev, V R; Sugarman, E A; Labrousse, P; Boguslavskiy, L; Flynn, K; Rohlfs, E M; Walker, A; Allitto, B; Sears, C; Scholl, T
- Year
- 2009
- Journal
- Journal of medical genetics
- PMID
- 19625283
- DOI
- 10.1136/jmg.2009.066969
- PMCID
- PMC2729371
BACKGROUND: Spinal muscular atrophy (SMA) is the most common inherited lethal disease of children. Various genetic deletions involving the bi-allelic loss of SMN1 exon 7 are reported to account for 94% of affected individuals. Published literature places the carrier frequency for SMN1 mutations between 1 in 25 and 1 in 50 in the general population. Although SMA is considered to be a pan-ethnic disease, carrier frequencies for many ethnicities, including most ethnic groups in North America, are unknown. OBJECTIVES AND METHODS: To provide an accurate assessment of SMN1 mutation carrier frequencies in African American, Ashkenazi Jewish, Asian, Caucasian, and Hispanic populations, more than 1000 specimens in each ethnic group were tested using a clinically validated, quantitative real-time polymerase chain reaction (PCR) assay that measures exon 7 copy number. RESULTS: The observed one-copy genotype frequency was 1 in 37 (2.7%) in Caucasian, 1 in 46 (2.2%) in Ashkenazi Jew, 1 in 56 (1.8%) in Asian, 1 in 91 (1.1%) in African American, and 1 in 125 (0.8%) in Hispanic specimens. Additionally, an unusually high frequency of alleles with multiple copies of SMN1 was identified in the African American group (27% compared to 3.3-8.1%). This latter finding has clinical implications for providing accurate adjusted genetic risk assessments to the African American population. CONCLUSIONS: Differences in the frequency of SMA carriers were significant among several ethnic groups. This study provides an accurate assessment of allele frequencies and estimates of adjusted genetic risk that were previously unavailable to clinicians and patients considering testing.
No figures extracted from this document.
1–9 of 9
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
| Citation | PMID | DOI | Status |
|---|---|---|---|
| AnhufDEggermannTRudnik-SchonebornSZerresK Determination of SMN1 and SMN2 copy number using TaqMan technology. Hum Mutat 2003;22:74–81281559610.1002/humu.10221 | — | — | — |
| CartegniLKrainerAR Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 2002;30:377–841192556410.1038/ng854 | — | — | — |
| ChanVYipBYamIAuPLinCKWongVChanTK Carrier incidence for spinal muscular atrophy in southern Chinese. J Neurol 2004;251:1089–931537225110.1007/s00415-004-0487-z | — | — | — |
| ChenKLWangYLRennertHJoshiIMillsJKLeonardDGWilsonRB Duplications and de novo deletions of the SMNt gene demonstrated by fluorescence-based carrier testing for spinal muscular atrophy. Am J Med Genet 1999;85:463–910405443 | — | — | — |
| ChenWJWuZYWangNLinMTMu-rongSX Quantitative studies on SMN1 gene and carrier testing of spinal muscular atrophy. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2005;22:559–60216331551 | — | — | — |
| CusinVClermontOGerardBChantereauDElionJ Prevalence of SMN1 deletion and duplication in carrier and normal populations: implication for genetic counselling. J Med Genet 2003;40:e391267691210.1136/jmg.40.4.e39PMC1735434 | — | — | — |
| FeldkötterMSchwarzerVWirthRWienkerTFWirthB Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002;70:358–681179120810.1086/338627PMC419987 | — | — | — |
| LabrumRRoddaJKrauseA The molecular basis of spinal muscular atrophy (SMA) in South African black patients. Neuromuscul Disord 2007;17:684–921762782210.1016/j.nmd.2007.05.005 | — | — | — |
| LefebvreSBurglenLReboulletSClermontOBurletPViolletLBenichouBCruaudCMillasseauPZevianiMLe PaslierDFrezalJCohenDWeissenbachJMunnichAMelkiJ Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155–65781301210.1016/0092-8674(95)90460-3 | — | — | — |
| LorsonCLHahnenEAndrophyEJWirthB A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999;96:6307–111033958310.1073/pnas.96.11.6307PMC26877 | — | — | — |
| MailmanMDHeinzJWPappACSnyderPJSedraMSWirthBBurghesAHPriorTW Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 2002;4:20–61183995410.1097/00125817-200201000-00004 | — | — | — |
| MailmanMDHemingwayTDarseyRLGlasureCEHuangYChadwickRBHeinzJWPappACSnyderPJSedraMSSchaferRWAbueloDNReichEWTheilKSBurghesAHde la ChapelleAPriorTW Hybrids monosomal for human chromosome 5 reveal the presence of a spinal muscular atrophy (SMA) carrier with two SMN1 copies on one chromosome. Hum Genet 2001;108:109–151128144810.1007/s004390000446 | — | — | — |
| OginoSGaoSLeonardDGPaesslerMWilsonRB Inverse correlation between SMN1 and SMN2 copy numbers: evidence for gene conversion from SMN2 to SMN1. Eur J Hum Genet 2003;11:275–71267328210.1038/sj.ejhg.5200957 | — | — | — |
| OginoSLeonardDGRennertHWilsonRB Spinal muscular atrophy genetic testing experience at an academic medical center. J Mol Diagn 2002;4:53–81182618810.1016/S1525-1578(10)60680-0PMC1906969 | — | — | — |
| OginoSWilsonRBGoldB New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet 2004;12:1015–231547036310.1038/sj.ejhg.5201288 | — | — | — |
| OpreaGEKroberSMcWhorterMLRossollWMullerSKrawczakMBassellGJBeattieCEWirthB Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 2008;320:524–71844092610.1126/science.1155085PMC4908855 | — | — | — |
| PearnJ Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 1978;15:409–1374521110.1136/jmg.15.6.409PMC1013753 | — | — | — |
| PriorTW Carrier screening for spinal muscular atrophy. Genet Med 2008;10:840–21894142410.1097/GIM.0b013e318188d069PMC3110347 | — | — | — |
| PyattREPriorTW A feasibility study for the newborn screening of spinal muscular atrophy. Genet Med 2006;8:428–371684527510.1097/01.gim.0000227970.60450.b2 | — | — | — |
| SmithMCalabroVChongBGardinerNCowieSdu SartD Population screening and cascade testing for carriers of SMA. Eur J Hum Genet 2007;15:759–661739270510.1038/sj.ejhg.5201821 | — | — | — |
| SuYNHungCCLiHLeeCNChengWFTsaoPNChangMCYuCLHsiehWSLinWLHsuSM Quantitative analysis of SMN1 and SMN2 genes based on DHPLC: a highly efficient and reliable carrier-screening test. Hum Mutat 2005;25:460–71583231010.1002/humu.20160 | — | — | — |
| WirthBHerzMWetterAMoskauSHahnenERudnik-SchonebornSWienkerTZerresK Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet 1999;64:1340–561020526510.1086/302369PMC1377870 | — | — | — |
| WirthBSchmidtTHahnenERudnik-SchonebornSKrawczakMMuller-MyhsokBSchonlingJZerresK De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling. Am J Hum Genet 1997;61:1102–11934510210.1086/301608PMC1716038 | — | — | — |
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Commentary for Special Issue of Prevention Science "Using Genetics in Prevention: Science Fiction or Science Fact?". | 2018 | 28735446 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A More Clinically Effective Long-Read Sequencing-Based Approach for Comprehensive Analysis of Spinal Muscular Atrophy. | Li S et al. | — | 2026 | → |
| Performance Evaluation of a PCR/Nanopore Assay for Carrier Screening for Cystic Fibrosis, Spinal Muscular Atrophy, and Fragile X Syndrome. | Martin KE et al. | — | 2026 | → |
| Analysis of spinal muscular atrophy patients from the spinal muscular atrophy and muscular dystrophy registry of Pakistan. | Aziz B et al. | — | 2025 | → |
| Carrier screening for survival motor neuron variants in 7709 pregnant women from Foshan, Guangdong Province. | Yuan XW et al. | — | 2025 | → |
| Prenatal carrier screening for spinal muscular atrophy among pregnant Thai women. | Tangshewinsirikul C et al. | — | 2025 | → |
| The Landscape of Genetic Variation and Disease Risk in Romania: A Single-Center Study of Autosomal Recessive Carrier Frequencies and Molecular Variants. | Gug M et al. | — | 2025 | → |
| A high-fidelity long-read sequencing-based approach enables accurate and effective genetic diagnosis of spinal muscular atrophy. | Bai J et al. | — | 2024 | → |
| Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care. | Henderson ML et al. | — | 2024 | → |
| In Search of Spinal Muscular Atrophy Disease Modifiers. | Chudakova D et al. | — | 2024 | → |
| <i>SMN2</i> Copy Number Association with Spinal Muscular Atrophy Severity: Insights from Colombian Patients. | Lamadrid-González J et al. | — | 2024 | → |
| [Natural history of spinal muscular atrophy type I]. | Vlodavets DV et al. | — | 2024 | → |
| Parental Experiences with Newborn Screening and Gene Replacement Therapy for Spinal Muscular Atrophy. | Meyer AP et al. | — | 2024 | → |
| Prenatal carrier screening for spinal muscular atrophy among Thai pregnant women | Tangshewinsirikul C et al. | — | 2024 | — |
| Spinal muscular atrophy: Molecular mechanism of pathogenesis, diagnosis, therapeutics, and clinical trials in the Indian context. | Aasdev A et al. | — | 2024 | → |
| Alberta Spinal Muscular Atrophy Newborn Screening-Results from Year 1 Pilot Project. | Niri F et al. | — | 2023 | → |
| An Effective and Universal Long-Read Sequencing-Based Approach for SMN1 2 + 0 Carrier Screening through Family Trio Analysis. | Li S et al. | — | 2023 | → |
| A new line method; A direct test in spinal muscular atrophy screening for DBS. | Kubar A et al. | — | 2023 | → |
| Comprehensive SMN1 and SMN2 profiling for spinal muscular atrophy analysis using long-read PacBio HiFi sequencing. | Chen X et al. | — | 2023 | → |
| Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis. | Abiusi E et al. | — | 2023 | → |
| Spinal muscular atrophy in Ghanaian children confirmed by molecular genetic testing: a case series. | Hammond CK et al. | — | 2023 | → |
| Studying carrier frequency of spinal muscular atrophy in the State of Qatar and comparison to other ethnic groups: Pilot study. | Ibrahim F et al. | — | 2023 | → |
| The Carrier Frequency of Two <i>SMN1</i> Genes in Parents of Symptomatic Children with SMA and the Significance of <i>SMN1</i> Exon 8 in Carriers. | Davidson JE et al. | — | 2023 | → |
| A case for genomic medicine in South African paediatric patients with neuromuscular disease. | Raga SV et al. | — | 2022 | → |
| Comprehensive Analysis of Spinal Muscular Atrophy: SMN1 Copy Number, Intragenic Mutation, and 2 + 0 Carrier Analysis by Third-Generation Sequencing. | Li S et al. | — | 2022 | → |
| Genetic architecture of motor neuron diseases. | Chaudhary R et al. | — | 2022 | → |
| Next generation sequencing is a highly reliable method to analyze exon 7 deletion of survival motor neuron 1 (SMN1) gene. | Zhao S et al. | — | 2022 | → |
| Overview of Neuromuscular Disorder Molecular Diagnostic Experience for the Population of Latvia. | Lace B et al. | — | 2022 | → |
| Recommendations for Interpreting and Reporting Silent Carrier and Disease-Modifying Variants in SMA Testing Workflows. | Milligan JN et al. | — | 2022 | → |
| Scalable detection of technically challenging variants through modified next-generation sequencing. | Rojahn S et al. | — | 2022 | → |
| The clinical utility of a risk-modifying SNP to detect carriers for spinal muscular atrophy with increased sensitivity. | Ware G et al. | — | 2022 | → |
| Carrier frequency of SMN1-related spinal muscular atrophy in north Indian population: The need for population based screening program. | Nilay M et al. | — | 2021 | → |
| Characterization of Reference Materials for Spinal Muscular Atrophy Genetic Testing: A Genetic Testing Reference Materials Coordination Program Collaborative Project. | Prior TW et al. | — | 2021 | → |
| Comprehensive Mutation Analysis and Report of 12 Novel Mutations in a Cohort of Patients with Spinal Muscular Atrophy in Iran. | Sharifi Z et al. | — | 2021 | → |
| Detection of Spinal Muscular Atrophy Using a Duplexed Real-Time PCR Approach With Locked Nucleic Acid-Modified Primers. | Pan J et al. | — | 2021 | → |
| Drug Discovery of Spinal Muscular Atrophy (SMA) from the Computational Perspective: A Comprehensive Review. | Chong LC et al. | — | 2021 | → |
| Genomic Variability in the Survival Motor Neuron Genes (<i>SMN1</i> and <i>SMN2</i>): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development. | Butchbach MER | — | 2021 | → |
| NGS-based spinal muscular atrophy carrier screening of 10,585 diverse couples in China: a pan-ethnic study. | Zhao S et al. | — | 2021 | → |
| Obligations of the "Gift": Reciprocity and Responsibility in Precision Medicine. | Lee SS | — | 2021 | → |
| Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). | Gregg AR et al. | — | 2021 | → |
| Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance. | Keinath MC et al. | — | 2021 | → |
| The Importance of Digging into the Genetics of <i>SMN</i> Genes in the Therapeutic Scenario of Spinal Muscular Atrophy. | Costa-Roger M et al. | — | 2021 | → |
| Beyond the "Jewish panel": the importance of offering expanded carrier screening to the Ashkenazi Jewish population. | Dolitsky S et al. | — | 2020 | → |
| Diagnostic Testing for Patients with Spinal Muscular Atrophy. | Brandsema JF et al. | — | 2020 | → |
| Incorporating Spinal Muscular Atrophy Analysis by Next-Generation Sequencing into a Comprehensive Multigene Panel for Neuromuscular Disorders. | Tan CA et al. | — | 2020 | → |
| Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data. | Chen X et al. | — | 2020 | → |
| Spinal Muscular Atrophy in the Black South African Population: A Matter of Rearrangement? | Vorster E et al. | — | 2020 | → |
| Beyond the Brochure: Innovations in Clinical Counseling Practices for Prenatal Genetic Testing Options. | Knutzen D et al. | — | 2019 | → |
| Carrier frequency of spinal muscular atrophy in Thailand. | Dejsuphong D et al. | — | 2019 | → |
| The frequency of SMN gene variants lacking exon 7 and 8 is highly population dependent. | Vijzelaar R et al. | — | 2019 | → |
| Accurate diagnosis of spinal muscular atrophy and 22q11.2 deletion syndrome using limited deoxynucleotide triphosphates and high-resolution melting. | Zhang X et al. | — | 2018 | → |
| Commentary for Special Issue of Prevention Science "Using Genetics in Prevention: Science Fiction or Science Fact?" | Dick DM | — | 2018 | → |
| Common and Founder Mutations for Monogenic Traits in Sub-Saharan African Populations. | Krause A et al. | — | 2018 | → |
| Expanded carrier screening: what the reproductive endocrinologist needs to know. | Dungan J | — | 2018 | → |
| Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. | GBD 2016 Motor Neuron Disease Collaborators | — | 2018 | → |
| Motor neuron biology and disease: A current perspective on infantile-onset spinal muscular atrophy. | Jha NN et al. | — | 2018 | → |
| Multiplex Droplet Digital PCR Method Applicable to Newborn Screening, Carrier Status, and Assessment of Spinal Muscular Atrophy. | Vidal-Folch N et al. | — | 2018 | → |
| Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. | Kraszewski JN et al. | — | 2018 | → |
| Spinal muscular atrophy within Amish and Mennonite populations: Ancestral haplotypes and natural history. | Carson VJ et al. | — | 2018 | → |
| Using Systems Biology and Mathematical Modeling Approaches in the Discovery of Therapeutic Targets for Spinal Muscular Atrophy. | Butchbach MER | — | 2018 | → |
| Utility of two SMN1 variants to improve spinal muscular atrophy carrier diagnosis and genetic counselling. | Alías L et al. | — | 2018 | → |
| Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States. | Lally C et al. | — | 2017 | → |
| Notable Carrier Risks for Individuals Having Two Copies of SMN1 in Spinal Muscular Atrophy Families with 2-copy Alleles: Estimation Based on Chinese Meta-analysis Data. | Wei X et al. | — | 2017 | → |
| Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. | Verhaart IEC et al. | — | 2017 | → |
| The next generation of population-based spinal muscular atrophy carrier screening: comprehensive pan-ethnic SMN1 copy-number and sequence variant analysis by massively parallel sequencing. | Feng Y et al. | — | 2017 | → |
| A Review on Spinal Muscular Atrophy: Awareness, Knowledge, and Attitudes. | Moultrie RR et al. | — | 2016 | → |
| Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. | Butchbach ME | — | 2016 | → |
| Does the survival motor neuron copy number variation play a role in the onset and severity of sporadic amyotrophic lateral sclerosis in Malians? | Sangare M et al. | — | 2016 | → |
| Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review. | Long C et al. | — | 2016 | → |
| New multiplex real-time PCR approach to detect gene mutations for spinal muscular atrophy. | Liu Z et al. | — | 2016 | → |
| Opinion commune de la SOGC et du CCGM sur le dépistage génétique en contexte de procréation : Mise à jour à l'intention de l'ensemble des prestataires canadiens de soins de santé maternelle et de services en procréation, à l'ère des tests offerts directement aux consommateurs. | Wilson RD et al. | — | 2016 | → |
| Spinal Muscular Atrophy: Overview of Molecular Diagnostic Approaches. | Prior TW et al. | — | 2016 | → |
| Detection of survival motor neuron protein in buccal cells through electrochemiluminescence-based assay. | Steinkellner H et al. | — | 2015 | → |
| Frequency of <i>SMN1</i> deletion carriers in a Mestizo population of central and northeastern Mexico: A pilot study. | Contreras-Capetillo SN et al. | — | 2015 | → |
| Newborn screening for spinal muscular atrophy: Anticipating an imminent need. | Phan HC et al. | — | 2015 | → |
| SMN1 and SMN2 copy numbers in cell lines derived from patients with spinal muscular atrophy as measured by array digital PCR. | Stabley DL et al. | — | 2015 | → |
| Spinal muscular atrophy: diagnosis and management in a new therapeutic era. | Arnold WD et al. | — | 2015 | → |
| Carrier screening for spinal muscular atrophy in Italian population. | Calì F et al. | — | 2014 | → |
| Genetics of low spinal muscular atrophy carrier frequency in sub-Saharan Africa. | Sangaré M et al. | — | 2014 | → |
| SMA carrier testing: a meta-analysis of differences in test performance by ethnic group. | MacDonald WK et al. | — | 2014 | → |
| Ten years of experience in molecular prenatal diagnosis and carrier testing for spinal muscular atrophy among families from Serbia. | Miskovic M et al. | — | 2014 | → |
| Anesthesia and spinal muscle atrophy. | Islander G | — | 2013 | → |
| How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches. | Wirth B et al. | — | 2013 | → |
| Public attitudes regarding a pilot study of newborn screening for spinal muscular atrophy. | Rothwell E et al. | — | 2013 | → |
| Spinal muscular atrophy: from gene discovery to clinical trials. | Nurputra DK et al. | — | 2013 | → |
| VPA response in SMA is suppressed by the fatty acid translocase CD36. | Garbes L et al. | — | 2013 | → |
| A population-based study of autosomal-recessive disease-causing mutations in a founder population. | Chong JX et al. | — | 2012 | → |
| Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. | Crawford TO et al. | — | 2012 | → |
| Homozygous SMN1 exons 1-6 deletion: pitfalls in genetic counseling and general recommendations for spinal muscular atrophy molecular diagnosis. | Thauvin-Robinet C et al. | — | 2012 | → |
| Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. | Sugarman EA et al. | — | 2012 | → |
| Pharmaceutical therapies to recode nonsense mutations in inherited diseases. | Lee HL et al. | — | 2012 | → |
| Raising obstetricians' awareness of spinal muscular atrophy: towards early detection and reproductive planning. | Parra J et al. | — | 2012 | → |
| Spinal muscular atrophy: a clinical and research update. | Markowitz JA et al. | — | 2012 | → |
| A common spinal muscular atrophy deletion mutation is present on a single founder haplotype in the US Hutterites. | Chong JX et al. | — | 2011 | → |
| Carrier screening for spinal muscular atrophy (SMA) in 107,611 pregnant women during the period 2005-2009: a prospective population-based cohort study. | Su YN et al. | — | 2011 | → |
| Detection of spinal muscular atrophy carriers in a sample of the Brazilian population. | Bueno KC et al. | — | 2011 | → |
| Identification of bidirectional gene conversion between SMN1 and SMN2 by simultaneous analysis of SMN dosage and hybrid genes in a Chinese population. | Chen TH et al. | — | 2011 | → |
| Lower incidence of deletions in the survival of motor neuron gene and the neuronal apoptosis inhibitory protein gene in children with spinal muscular atrophy from Serbia. | Miskovic M et al. | — | 2011 | → |
| New approaches in molecular diagnosis and population carrier screening for spinal muscular atrophy. | Gonçalves-Rocha M et al. | — | 2011 | → |
| Population carrier screening for spinal muscular atrophy a position statement of the association for molecular pathology. | Muralidharan K et al. | — | 2011 | → |
| Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses. | Kobayashi DT et al. | — | 2011 | → |
| Carrier testing for spinal muscular atrophy. | Gitlin JM et al. | — | 2010 | → |
| Compound muscle action potential and motor function in children with spinal muscular atrophy. | Lewelt A et al. | — | 2010 | → |
| Determination of SMN1 and SMN2 copy numbers in a Korean population using multiplex ligation-dependent probe amplification. | Yoon S et al. | — | 2010 | → |
| Neuromuscular defects and breathing disorders in a new mouse model of spinal muscular atrophy. | Michaud M et al. | — | 2010 | → |
| Newborn and carrier screening for spinal muscular atrophy. | Prior TW et al. | — | 2010 | → |
| Outcome and experience of implementing spinal muscular atrophy carrier screening on sperm donors. | Callum P et al. | — | 2010 | → |
| Rapid diagnosis of spinal muscular atrophy using tetra-primer ARMS PCR assay: simultaneous detection of SMN1 and SMN2 deletion. | Baris I et al. | — | 2010 | → |
| Spinal muscular atrophy: a time for screening. | Prior TW | — | 2010 | → |
| Spinal muscular atrophy: newborn and carrier screening. | Prior TW | — | 2010 | → |
| The clinical context of copy number variation in the human genome. | Lee C et al. | — | 2010 | → |